Accordingly, substantial efforts have been devoted to targeting the receptor tyrosine kinase (RTK)/RAS/MAPK pathway (6), yielding numerous small-molecule inhibitors of pathway components RTKs, KRAS, RAF, MEK1/2, and ERK1/2 that show efficacy in cancer patients (7–10). This evidence concerns the gene KRAS and cancer.